ArticleBMC health services research2026
Evaluation of availability and affordability of lung cancer drugs in Central China: a cross-sectional study.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeLung cancer remains the leading cause of cancer-related morbidity and mortality in China, yet systemic inequalities in drug accessibility persist. The present study aimed to investigate the availability and affordability of 23 anticancer drugs for lung cancer in Central China.
methodsA cross-sectional study was conducted from December 2022 to July 2023 across 62 hospitals in Central China using the WHO/HAI standardized methodology. Drug availability was defined as the proportion of hospitals stocking medicines on the survey day, while affordability was assessed as treatment costs ≤ 20% of household income. Supplemental procurement time (SPT) measuring restocking time for unavailable drugs, was introduced to evaluate availability dynamics.
resultsOnly 34.8% of drugs met WHO availability thresholds (>80%). Traditional chemotherapies (e.g., cisplatin, gemcitabine) showed high availability (> 80% in tertiary hospitals) but remained unaffordable for low-income households (e.g., docetaxel originator brands (OBs): 288.62-374.27% of monthly income). Unlike conventional availability metrics, our SPT index revealed rapid restocking (≤ 72 h) for 69.4% of anlotinib-a dynamic accessibility dimension previously unmeasured in oncology drug studies. Whereas crizotinib faced delays (> 1 month) in 43.55% of hospitals, undetected by traditional methods.
conclusionWe found that the availability of anticancer drugs for lung cancer is extremely unequal, and only a few medicines were considered affordable. Further efforts should be made to sufficiently and equally benefit patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.